ARCHIVES

MGI Pharma’s Irofulven In Phase III Trial Vs. 5-FU For Advanced Pancreatic Cancer.

This article is from The Cancer Letter archive.

Vol. 27 No. 09 | March 2, 2001

Download PDF Visit The Full Archive

Related Articles

Q&A: Data that Killed CYP2D6 Testing Contradict Fundamental Law of Nature

May 18, 2012

Continuing Resolution Averts Shutdown; Locks in Sequestration Cuts for NIH, NCI

March 22, 2013

Reauthorization Still Held up

September 30, 1988

AACR Supports Bypass Budget; Public Consortium Sequences Mouse Genome

May 10, 2002

NIH awards 1,400 student loan repayment contracts.

October 29, 2004

In Brief NCI-FDA Relations Tops, DeVita Says; Upon Talks to Candidates For Prospective Division

November 24, 1978